U.S. Markets closed

Amphastar Pharmaceuticals, Inc. (AMPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.89+0.15 (+0.85%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close17.74
Open17.73
Bid17.89 x 900
Ask17.90 x 800
Day's Range17.67 - 17.92
52 Week Range14.77 - 22.69
Volume88,758
Avg. Volume204,871
Market Cap848.575M
Beta (5Y Monthly)0.76
PE Ratio (TTM)596.33
EPS (TTM)0.03
Earnings DateMar 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.20
  • Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
    Simply Wall St.

    Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • GlobeNewswire

    Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

    RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 pm Eastern time. This presentation will be made available webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation. About Amphastar: Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company’s website at www.amphastar.com. The Amphastar Pharmaceuticals’ logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc. Forward Looking Statements All statements in this press release that are not historical are forward-looking statements. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 15, 2021. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar’s expectations to change. Contact: Bill Peters Chief Financial Officer (909) 476-3416

  • FDA Approves New Drug Application For Amphastar’s Dextrose Injection
    SmarterAnalyst

    FDA Approves New Drug Application For Amphastar’s Dextrose Injection

    Amphastar Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Dextrose injection 50% in the 50 ml Luer-Jet Prefilled Syringe System. Amphastar (AMPH) has sold and marketed the injection under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program over the last 40 years. Notably, the Dextrose injection generated net revenues of $7.6 million for the year ended Dec. 31, 2020. Amphastar CEO Dr. Jack Zhang said, “The FDA’s approval of Dextrose, a product often on the Agency’s Drug Shortage list, offers an opportunity to ensure quality products are produced at the highest standard and highlights Amphastar’s manufacturing capabilities to fulfill such market needs.” Earlier this month, Amphastar reported 4Q results. The company’s 4Q adjusted earnings more than doubled on a year-over-year basis to $0.16 per share and outpaced Street estimates of $0.14. Revenues increased 15% to $95.9 million and exceeded analysts’ expectations of $88.94 million. (See Amphastar stock analysis on TipRanks) On March 15, Needham analyst Serge Belanger maintained a Hold rating on the stock, as the analyst believes “AMPH’s valuation embeds the upside of near-term approvals.” The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating. That’s based on 2 analysts suggesting a Buy and 3 analysts recommending a Hold. The average analyst price target of $22.33 implies a 23.3% upside potential to current levels. Shares have increased 19.8% over the past year. Related News: Medtronic Receives FDA Approval For Harmony TPV Therapy; Street Says Buy Johnson & Johnson Signs Single-Shot COVID-19 Vaccine Deal With AVAT Cognizant To Snap Up ESG Mobility, Boost Digital Automation More recent articles from Smarter Analyst: Millendo To Merge With Tempest Therapeutics; Shares Tank Tuesday’s Pre-Market: Here’s What You Need To Know Before The Market Opens Comcast Rolls Out Disney+ And ESPN+ On Xfinity Canoo’s 4Q Loss Improves On Electric Vehicles Strength